TNFRSF8 and cancer: The linker-toxin entity used in our work, vc-MMAE, was originally developed in pioneering studies to create the ADC Brentuximab Vedotin (Adcetris®), directed against CD30-positive cancers [26, 27, 43, 44]], and since then, vc-MMAE has been widely used in ADC development [21, 42].